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Aims Thermal injury to the oesophagus is an important cause of life-threatening complication after ablation for atrial fi-
brillation (AF). Thermal protection of the oesophageal lumen by infusing cold liquid reduces thermal injury to a lim-
ited extent. We tested the ability of a more powerful method of oesophageal temperature control to reduce the
incidence of thermal injury.
...................................................................................................................................................................................................
Methods and
results
A single-centre, prospective, double-blinded randomized trial was used to investigate the ability of the ensoETM
device to protect the oesophagus from thermal injury. This device was compared in a 1:1 randomization with a
control group of standard practice utilizing a single-point temperature probe. In the protected group, the device
maintained the luminal temperature at 4C during radiofrequency (RF) ablation for AF under general anaesthesia.
Endoscopic examination was performed at 7 days post-ablation and oesophageal injury was scored. The patient and
the endoscopist were blinded to the randomization. We recruited 188 patients, of whom 120 underwent endos-
copy. Thermal injury to the mucosa was significantly more common in the control group than in those receiving
oesophageal protection (12/60 vs. 2/60; P = 0.008), with a trend toward reduction in gastroparesis (6/60 vs. 2/60,
P = 0.27). There was no difference between groups in the duration of RF or in the force applied (P value range=
0.2–0.9). Procedure duration and fluoroscopy duration were similar (P = 0.97, P = 0.91, respectively).
...................................................................................................................................................................................................
Conclusion Thermal protection of the oesophagus significantly reduces ablation-related thermal injury compared with standard
care. This method of oesophageal protection is safe and does not compromise the efficacy or efficiency of the ab-
lation procedure.
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Introduction
Although its incidence is less than one per thousand cases, atrio-
oesophageal fistula is among the most common lethal complications
of ablation performed for atrial fibrillation (AF) or left atrial tachycar-
dia.1 Both radiofrequency (RF) ablation and cryoablation have been
associated with this complication.1,2 Mild degrees of thermal injury to
the oesophagus can be seen on endoscopy after ablation in up to
47% of patients,3 and the incidence of these mild lesions correlate
with the risk of fistula. Symptomatic alterations to gastric motility
from thermal injury to the peri-oesophageal neural plexus occur be-
tween 5% and 74% of cases.4,5 Many strategies have been proposed
to lower the risk to the oesophagus, but none has shown consistent
evidence of effectiveness.
The ensoETM device (Attune Medical, Chicago, IL, USA) is rou-
tinely used to control body temperature in patients who are prone
to hypothermia or hyperpyrexia in an intensive care setting, or
whose body temperature must be lowered to protect an injured
brain.6,7 As it does so by warming or cooling the lumen of the oe-
sophagus and stomach, we hypothesized that it might protect the oe-
sophagus from localized thermal injury by controlling the local
temperature.
Methods
Trial design
The IMPACT study was an investigator-initiated single-centre, prospec-
tive, double-blind randomized controlled trial (Figure 1). The study cohort
consisted of adult patients receiving AF ablation under general anaesthe-
sia. Recruitment ran from February 2019 to January 2020. The study was
approved by the London-Stanmore Research Ethics Committee (IRAS ID
253844, NIHR CPMS ID 40619) and registered on ClinicalTrials.gov
NCT03819946.
Study population
All adult patients attending or already listed for radiofrequency ablation
for AF or LAT under general anaesthesia by participating electrophysiolo-
gists at our centre were screened during pre-assessment. Patients who
did not consent to undergo post-procedure endoscopy were excluded.
Participants were randomly assigned in a 1:1 design (via electronic ran-
domization www.sealedenvelope.com) to either receive thermal protec-
tion with the ensoETM device or standard care consisting of the use of a
single sensor temperature probe. Patients were blinded to the treatment
assignment.
Protected group: the ensoETM device
The ensoETM device is a medical-grade silicone tube (dimensions: 75 cm
in length and 1.2 cm outer diameter; Figure 2) through which distilled wa-
ter is pumped in a closed-loop irrigation system: no water enters the gas-
trointestinal tract of the patient. There is an additional inner lumen that
can be used for gastric aspiration like a standard nasogastric tube. The
non-patient end of the device is connected to a Blanketrol III mobile con-
sole (Gentherm Medical, Cincinnati, OH, USA) that pumps the water and
controls its temperature. The ensoETM device maintains the water at a
thermostat-controlled set temperature chosen by the operator between
4C and 42C. During operation, the water volume in the tubing is 55 mL
and it flows at 2.4 L/min exerting a maximum pressure of 103 kPa.
Protected group
Patients assigned to receive oesophageal protection underwent prepara-
tion for ablation in the standard fashion with transoesophageal echocardi-
ography performed as soon as anaesthesia was induced. After using
transoesophageal echocardiography to guide transseptal puncture, the
probe was withdrawn and an ensoETM probe was introduced in its place,
connected to a Blanketrol III, mobile console.8 The position was con-
firmed radiographically, aiming to place the distal end of the device below
the diaphragm (Figure 3). Before beginning ablation on the posterior part
of the left atrium, the probe was set to cooling mode at 4C for at least
10 min. Cooling continued until ablation was complete. External body
temperature was recorded throughout with a temperature probe placed
in the axilla or nasopharynx.
Control group
A single-sensor temperature probe (Level 1VR Oesophageal Temperature
Probe, Smiths Medical, Minneapolis, MN, USA, was used) was placed in
the oesophagus by the attending anaesthetist and adjusted approximately
to the site of ablation. Adjustment of the position of the probe during ab-
lation was performed by the anaesthetist under the direction of the oper-
ating electrophysiologist with the objective of keeping the tip of the
probe as close as possible to the site of ablation whenever the site was
within 1 cm of the oesophagus. RF delivery was suspended if the tempera-
ture indicated by the probe exceeded 38C and RF was not resumed at
that location until the temperature fell below 37C. To avoid delay, oper-
ators often moved to a location distant from the oesophagus to continue
work while waiting for the temperature to fall.
Body temperature management and
anaesthesia
In all cases, standard anaesthetic methods were used, with intravenous in-
duction using propofol and a non-depolarizing muscle relaxant followed
by endotracheal intubation and maintenance with a volatile anaesthetic.
Whole body warming was with a heated air-blanket (Bair HuggerTM, 3M,
St. Paul, MN, USA). The settings on the warming blanket were controlled
by the anaesthetist to maintain a body temperature of >35–37C
throughout the procedure. The anaesthetist used the oesophageal tem-
perature probe to judge this in the control patients, axillary, nasal, or au-
ricular temperature in study patients.
What’s new?
• The ensoETM device is routinely used in critical care to con-
trol body temperature by warming or cooling the lumen of the
oesophagus and stomach in the range 4–42C.
• Previous studies on oesophageal cooling by infusion of water
during ablation for atrial fibrillation have shown evidence of
protection despite the limited heat-extraction achievable by
this method.
• In a double-blind randomized trial, patients whose oesopha-
geal temperature was maintained at 4C during ablation for
atrial fibrillation suffered fewer thermal injuries to the oesoph-
agus than patients receiving standard treatment.
• Oesophageal protection by the ensoETM device did not slow
the procedure or reduce its effectiveness.
2 L.W.M. Leung et al.
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Proton pump inhibitors
All participants in this study received proton pump inhibitors (PPI) initi-
ated immediately post-ablation for a period of 8 weeks in accordance
with standard practice at our centre.
Method of RF ablation
Catheter ablation was performed using irrigated contact force sensing
catheters (STSF or Qdot Micro, Biosense Webster, Johnson and
Johnson, Diamond Bar, CA, USA) with a 3D mapping system (CartoVR
version 6 and 7, Biosense Webster) with Ablation Index (AI) technology.
A double trans-septal approach was used, and additional mapping was
done using a Lasso-Nav or Pentaray mapping catheter (Biosense
Webster). Lesions in the anterior part of the left atrium were created at
40 W with an AI target of 450–500; posterior lesions were at 30 W with
an AI target of 350–400.
Endoscopy
All patients were invited to attend for endoscopy at 7 days after ablation.
Endoscopy was performed by one of two senior endoscopists following a
standardized protocol with detailed inspection of the anterior wall of the
mid-oesophagus. The patient and the endoscopist were blinded to the
treatment assignment of the patient. Any lesions observed were catego-
rized according to a scoring system which was devised for the study and
represents a refinement of the Kansas City Classification, with a greater
degree of gradation in the moderate range of lesion severity that we
expected to find (Figure 4). The stomach was inspected for evidence of
Enrolment Assessed for eligibility (n=198)
All AF ablation candidates screened
at pre-assessment
Randomized (n = 188)
Allocation
1:1
randomizationAllocated to intervention- to receive
esophageal cooling during AF ablation (n = 93)
•   Received allocated intervention (n = 93)
•   Did not receive allocated intervention (n = 0)
Allocated to control- to receive single-sensor
esophageal temperature monitoring during AF
ablation (n = 95)
•   Received allocated intervention (n = 95)
•   Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analysed (n = 60)
      •    Excluded from primary endpoint analysis
           (n = 33 due to participant withdrawing consent for
           follow up endoscopy after ablation treatment.)
N = 93 all undergoing:
      •    Structured symptoms assessment at 1st
           clinical follow up ~3 months.
      •    Long term follow up at 3, 6, 12 months:
           freedom from treated arrhythmia and
           MACCE.
Analysed (n = 60)
      •    Excluded from primary endpoint analysis
           (n = 33 due to participant withdrawing consent for
           follow up endoscopy after ablation treatment.)
N = 93 all undergoing:
      •    Structured symptoms assessment at 1st
           clinical follow up ~3 months.
      •    Long term follow up at 3, 6, 12 months:
           freedom from treated arrhythmia and
           MACCE.
Study follow-up
Anaysis
Excluded (n = 10)
•   Not meeting inclusion criteria (n = 0)
•   Declined to participate (n = 8)
•   Other reasons (n = 2)
Figure 1 Consort 2010 flow diagram for the IMPACT study. All patients attending for left atrial ablation by participating physicians were consid-
ered. Almost all agreed to participate, but 36% subsequently declined to return for their scheduled endoscopy at 1 week post-ablation.
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dysmotility. Gastroparesis was defined as the presence of food material in
the stomach after >8 h of fasting.
Assessment of symptoms
Patients underwent a structured assessment for upper GI symptoms
according to the Gastro-Oesophageal Reflux Disease (GERDQ) ques-
tionnaire; the Gastroparesis Cardinal Symptoms Index (GCSI)
questionnaire was used to probe for typical features of gastric dysmotility.
Specific supplementary questions were added to quantify post-proce-
dural chest pain and the overall unpleasantness of the patient experience
on a scale of severity from 0 to 10 (10 = most severe or worst experi-
ence). Administration of the questionnaires was at the first clinical follow-
up post-ablation at 1–3 months post-ablation by members of the re-
search study without access to the randomization of the participants.
Figure 2 The ensoETM device. The ensoETM device (A and B) and the connectors to the Blanketrol III mobile console (C). The white elements at
the tip of the ensoETM and in a strip along its length are radio-opaque.
Figure 3 Radiological images of the device during use. (A) a right anterior oblique view of a device at the correct level of placement. Only the radio-
opaque strip is clearly seen (white arrow). (B) a device positioned with the radio-opaque tip above the level of the diaphragm. It was advanced an addi-
tional 10 cm before ablation commenced.
4 L.W.M. Leung et al.
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Arrhythmia follow-up
Patients were reviewed at 3- and 6-month post-ablation and underwent
ambulatory ECG monitoring between these visits; 12-month follow-up
will occur. Standard ECG monitoring devices were used for follow-up, in-
cluding 12-lead ECG at all follow-up visits in all patients, data download
from implantable loop recorders, pacemakers, and defibrillators when
available, ambulatory ECG of >_24 h in all other patients. Any occurrence
of atrial tachyarrhythmia at >3 months post-ablation was considered to
represent a failure of the procedure.
Power calculation
Based on a pre-study clinical estimate of 15% incidence of lesions in the
control group from prior local experience and literature from elsewhere,
and an incidence of 1% in the study group based on our own pre-trial
use of the device, we calculated a sample size of 120 with endoscopic as-
sessment to achieve a study power of 0.80 to answer the hypothesis.
Endpoints
The primary endpoint of the study was the incidence of endoscopically
detected oesophageal mucosal lesions and/or gastroparesis. Secondary
endpoints included the presence of post-procedure symptoms revealed
by the validated questionnaires GERD-Q and GCSI, the incidence of pro-
cedural complications and subsequent major adverse cardiovascular ce-
rebrovascular events (MACCE), and the technical and clinical success of
the procedure and indices of the difficulty of the procedure.
Technical success was defined as isolation of the pulmonary veins and
proven block across any other line of lesions delivered; clinical success
was also measured as freedom from the treated arrhythmia at >3 months
after ablation. Major adverse cardiovascular cerebrovascular event was
defined as MI/CVA, all-cause mortality, vascular trauma needing surgery,
cardiac tamponade, atrio-oesophageal fistula, and hospital acquired infec-
tion. The duration of the procedure and duration of fluoroscopy was
documented in all cases, as well as ablation delivery parameters including
total RF ablation time, power, force, FTI, and combined AI.
Statistical analysis
Analysis was performed with IBM SPSS statistical software (Version 22.0,
IBM SPSS Statistics, NY, USA) using Student’s t-test, v2 test, and Fisher’s
exact test as appropriate.
Ethical approval
Ethically approved by the London-Stanmore Research Ethical
Committee (IRAS ID 253844).
Results
Patients were recruited from 22 February 2019 to 13 January 2020.
More than 90% of patients screened for recruitment agreed to partic-
ipate, but 36.2% of recruited patients subsequently expressed unwill-
ingness or inability to return for endoscopy. Drop-out from
endoscopic follow-up occurred equally in the protected and control
groups. A total of 188 participants were recruited (89 protected and
99 control) of whom 120 (60 protected and 60 control) underwent
endoscopic examination.
There was no defining characteristic in the endoscopy drop-out
cohort who had similar baseline characteristics and procedure char-
acteristics to those who attended for endoscopy (Supplementary
material online, Table S1). A variety of reasons for endoscopy drop
out were cited, mostly relating to the logistical difficulty of attending
another hospital appointment but also including a need to spend
more time at home to recover from the ablation. Because the pri-
mary endpoints of the study were the endoscopic findings, the results
are quoted in this manuscript for the 120 patients who completed
the entire study protocol including endoscopy. All 188 patients re-
main under follow-up: their data are available in Supplementary mate-
rial online, Tables.
Figure 4 The St. George’s Modified Scoring System. For the purposes of the trial, we designed a modified system for categorizing endoscopically
detected iatrogenic thermal mucosal lesions. It is more finely graded than the Kansas City Classification (KCC), the classes of which are shown in
comparison.
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Patient and procedure characteristics
The baseline characteristics of the groups were well matched
(Table 1). The use of oesophageal cooling was not associated with
any difference in the procedure duration, nor was there any evidence
that its use made the accomplishment of procedural endpoints more
difficult. The duration of RF delivery, including RF delivery to the pos-
terior wall was similar in the protected and the control groups
(Table 2). All veins were isolated in all subjects in both groups, and all
veins remained isolated at the end of the procedure.
Linear ablation lesion sets across the roof of the left atrium, the
posterior wall of the left atrium and the posterior mitral isthmus
were each attempted at similar proportions of the protected cases
and in the control group with a similar rate of success in both. The to-
tal number of lesions and the duration of RF delivery required to
achieve procedural endpoints was similar in the control and the pro-
tected group, both among those who received PVI only and amongst
those receiving more extensive lesion sets (Table 2). Because it is our
policy to isolate the posterior wall of the left atrium in patients who
return for repeat ablation and are found to have prior isolation of
three or more veins did some ablation in the posterior left atrium in
all trial patients. Of the 23 patients, 16 had enduring posterior wall
isolation in the protected group compared with 19/23 patients in the
control group (P = 0.49; Table 2). No temperature rise above 43C
was recorded in the oesophagus of any patient.
Primary endpoint analysis—endoscopy
findings
Endoscopy demonstrated significantly fewer thermal injuries in
patients protected by the ensoETM compared with the control
group (2/60 vs. 12/60, P = 0.008; Figure 5). Gastroparesis was present
in 2/60 protected patients, 6/60 patients in the control group
(P = 0.27). There were no endoscopy findings consistent with trauma
from the ensoETM device or from trans-oesophageal echo.
Moderate to severe (Grade 4 or more) lesions occurred in one case
in the protected group, six cases of the control group (P = NS).
The only moderately severe lesion in the protected group related
to a protocol breach: the patient in question exhibited a recurrence
of conduction into the right pulmonary veins as the procedure was
finishing, and the operator delivered additional lesions at a site on the
posterior margin of the right inferior vein, unaware that the oesopha-
geal cooling had been turned off 20 min earlier. The event was dis-
cussed after the protocol breach was noticed, but the patient
continued in the study as the intention had been to protect through-
out the procedure. The endoscopist was unaware of the treatment
assignment or the deviation from protocol. The site of the lesion was
in keeping with the delivery in question.
Other than the use of the ensoETM device, we were not able to
identify significant predictors of the occurrence of mucosal lesions.
They were non-significantly more frequent in patients who received
a line of ablation across the posterior wall of the left atrium (Table 3),
but they did not follow the expected pattern of higher prevalence in
leaner patients, nor did they occur more frequently in patients with
prior gastrointestinal complaints including Barrett’s oesophagus.
Secondary endpoints—major adverse
cardiovascular cerebrovascular events
There was no significant difference in acute complication rates be-
tween the protected and control groups. There were two cases of
acute vascular trauma needing intervention with thrombin injection
in the control group and one case of additional hospital night stay due
to post-procedural bradycardia. There were two cases of extra hos-
pital night stay in the protected group, of which one was planned pre-
ablation due to previous adverse reaction to Heparin. The other case
was due to a small pericardial effusion that was conservatively man-
aged. There were no acute cases of tamponade, MI, CVA, or death in
either group. There was one case of late mortality in the protected
group, a patient who died at between 3- and 6-month post-ablation
due to progression of pre-existing severe heart failure. All other
patients were discharged the day after the procedure and remained
well until 6 months or the last available follow-up.
Procedural workflow
Fluoroscopy and procedure duration were similar in both groups.
Recovery time was also similar with no difference in hospital night
stay between the two groups (Table 2).
....................................................................................................................................................................................................................
Table 1 Patient and procedure characteristics
Patient and procedure
characteristics
Protected (n 5 60) Control (n 5 60) P-value
Male n = 36 (60%) n = 37 (61.7%) 0.85
Mean age (years) 65 ± 10 65 ± 9 0.9
Left atrial diameter (cm) 4.1 ± 0.9 4.2 ± 0.6 0.48
LV ejection fraction (%) 55 ± 9 52 ± 8 0.24
BMI (kg/m2) 28.5 ± 5.3 29.8 ± 6.98 0.25
Paroxysmal AF, first time ablation n = 27 (45%) n = 30 (50%) 0.71
Persistent AF, first time ablation n = 24 (40%) n = 20 (33.4%) 0.57
Repeat left atrial ablation n = 8 (13.3%) n = 9 (15%) 0.79
Left atrial tachycardia n = 1 (1.7%) n = 1 (1.7%) 1
AF, atrial fibrillation; BMI, body mass index; LV, left ventricular.
6 L.W.M. Leung et al.
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Patient symptoms—relationship to
protection and endoscopic findings
The combined questions of GERD-Q and GCSI covered a wide range
of gastro-oesophageal or gastroparetic symptoms that could occur
after an ablation, and the occurrence of chest pain. Results of the
questionnaires were available in all patients who reached the 3-
month follow-up point. The majority of the study participants did not
experience significant gastrointestinal symptoms post-ablation, as
scored by the GERD-Q and GCSI questionnaires (Table 2). The pres-
ence of mucosal lesions did not correlate strongly with symptoms,
confirming previous literature which has shown that many patients
who sustain mucosal lesions remain asymptomatic. Those who had
signs of gastroparesis on endoscopy were generally symptomatic.
The overall symptom burden was similar in the protected and the
control groups.
Clinical outcome
Clinical follow-up has been disrupted since late February 2020 due to
the COVID-19 pandemic. All patients remain in telephone contact,
but attendances for ECG have been suspended. At the time when
disruption began, no patient had reached their 12-month follow-up
and only 50/120 and 82/120 had reached the 6-month and 3-month as-
sessment (Supplementary material online). Recurrence of AF or AT
outside the blanking period was equally common in the protected
group vs. the control group (Table 2). Follow-up of the study subjects is
ongoing.
Discussion
This prospective double-blind randomized controlled trial demon-
strates that endoscopically detected thermal injury to the
....................................................................................................................................................................................................................
Table 2 Procedural metrics and follow-up
Procedure metrics Protected (n 5 60) Control (n 5 60) P-value
Procedure duration (min) 186 ± 47 187 ± 48 0.9
Fluoroscopy duration (min) 10.9 ± 7.3 11.1 ± 7.4 0.88
Total RF time (s) 2066 ± 1062 2315 ± 1053 0.20
RF duration (posterior wall only),
median (IQR)
13.1 (10.3–17.5) 12.1 (9.1–15.8) <0.001 (z score: 4.073524)
AI values (posterior wall only), me-
dian (IQR)
379.7 (362.8–406.7) 377.2 (360–406.2) 0.57 (z score: 0.570419)
Achievement of PV isolation 60/60 (100%) 60/60 (100%) 1
First pass PV isolation achieved (first
time ablations cases)
45/51 (88.2%) 42/50 (84%) 0.58
Reconnection of PV during waiting
period or adenosine test (first
time ablations only)
1/51 (1.9%) 7/50 (14.9%) 0.03
Posterior wall isolation (persistent
or recurrent cases only)
16/23 19/23 0.49
Acute complications 1 2 0.56
Hospital stay >1 night 1 1 1
MACE—within 3 months 0 0 1
MACE—within 6 months 1 0 0.31
Arrhythmia recurrence during fol-
low-up
2 3 0.65
Re-admission to hospital 1 2 0.56
Re-ablation since index procedure 0 0 1
Moderate to severe grade symp-
toms as graded by GCSI (>19–
45), GERD-Q (7–18) or chest
pain scale (1–10) on 1st outpa-
tient follow-up
2 2 1
All positive symptoms recorded
from GCSI, GERD-Q, or chest
pain scale during 1st outpatient
follow-up
5 10 0.27
GCSI, Gastroparesis Cardinal Symptom Index; GERD-Q, Gastro-oesophageal Reflux Disease Questionnaire; IQR, interquartile range; MACE, major adverse cardiovascular
event; PV, pulmonary vein; RF, radiofrequency.
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oesophagus is less frequent when the ensoETM device is used to con-
trol the local temperature of the oesophageal lumen during RF abla-
tion for AF. This is the first randomized clinical study to show
superiority of this method of oesophageal protection over standard
care.
Secondary endpoints
The analyses on the secondary endpoints show that controlled active
thermal protection of the oesophagus utilizing the ensoETM device is
safe, with no difference in MACCE rates or acute complications
when compared with the control group cases. Endoscopy did not
show any evidence of oesophageal trauma attributable to the
ensoETM device. Procedure workflow and acute success were unaf-
fected by the device and at the 6-month time point, there is no effect
on the efficacy of the ablation.
Thermal injury to the oesophagus
Lesions of the oesophageal mucosa are common after AF ablation.
This is widely recognized for RF and also well documented for those
who receive cryoablation. Schemes of classification have been de-
vised to reflect this gradation of prognostic importance. The com-
monly used Kansas City Classification9 has six levels of severity
including zero for normal; our more graded classification has eight
levels, providing a higher level of discrimination which we believe to
be useful in demonstrating trends in lesion severity as well as
incidence.
There is no correct time for endoscopy after ablation. Our trial
was unusual among studies of post-ablation injury in choosing a 7-day
time point for endoscopy. Most thermal lesions are transient, consist-
ing of erythema that resolves within days. Mechanical injury to the oe-
sophagus from echo probes, temperature probes, or protective
Figure 5 Primary endpoints of the IMPACT trial. The endpoints were all derived from endoscopy. Mucosal lesions were significantly less common
after ablation carried out with the protection of the ensoETM device, with a trend toward reduction in gastroparesis. The only moderately severe le-
sion in a protected patient related to a protocol breach.
....................................................................................................................................................................................................................
Table 3 Factors associated with the occurrence or absence of mucosal lesions detected on endoscopy
Patients with mucosal lesions
(n 5 14)
Patients without mucosal
lesions (n 5 106)
P-value
Use of ensoETM device n = 2 n = 58 0.008
Posterior left atrial ablation line n = 8 n = 38 0.15
Age (years) 65.5 ± 5.4 SD 65.2 ± 5.8 0.85
Body mass index (kg/m2) 29.7 ± 5.6 SD 28.6 ± 5.6 0.49
Prior active GI condition n = 0 n = 6 0.46
GI: gastrointestinal.
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devices would be expected to follow a similar time-pattern.
Moderately severe lesions appear soon after ablation but heal within
weeks. Ulceration of the mucosa is known to be linked to progres-
sion towards fistula formation,10,11 a complication that typically
presents clinically at between 2 and 4 weeks after ablation.
We chose 7 days as the ideal interval between ablation and endos-
copy based on the available literature as the optimum for detecting
significant lesions without being overwhelmed by trivial findings. A
systematic review showed that with up to 47% incidence of all muco-
sal lesions at endoscopy performed at 24 h post-procedure,3,12 differ-
entiation between minor lesions and those worthy of attention was
difficult; endoscopy performed at an interval of 7–14 days from the
time of ablation gave far greater discrimination.10 By performing en-
doscopy later than most, we may have missed some of the milder
lesions and lost statistical power; it also makes our data less easy to
compare with previously published work.
We recognize that any single endoscopic assessment has limita-
tions. There is still a risk of falsely declaring a case as ‘all clear’; previ-
ous reports show anomalous cases having no mucosal lesions
detected at endoscopy 18 days post-ablation but nonetheless pro-
gressing to perforation or fistula.5 Despite this limitation, endoscopic
examination is still our best diagnostic tool. Computerized tomogra-
phy has a poorer performance, with far greater numbers of false-neg-
ative reports but is a recognized current 1st line diagnostic test for
emergent cases of suspected atrio-oesophageal fistula.13
Patient symptoms
This study confirms that those who sustain endoscopically detected
mucosal lesions in the oesophagus correlate poorly with patient
symptoms. Only those who have signs of gastroparesis on endoscopy
also have a clearly defined excess of symptoms as scored by the
GCSI questionnaire. Overall, the majority of AF ablation patients re-
cover smoothly with no significant gastrointestinal symptoms or
chest pain.
Preventing atrio-oesophageal fistula
Strategies have been tried for the prevention of fistula including the
administration of proton-pump inhibitors to facilitate oesophageal
healing. This has intuitive appeal but no backing in trial evidence.3,14 It
is based on the assumption that gastric acid contributes to the injury
that progresses to fistula formation; it is equally likely that bacterial
action is the prime driver for this progression and acidity might be
regarded as protective in its bactericidal effect.
Mechanical deviation of the oesophagus away from the point of ab-
lation has been investigated extensively. The most common method
involves manipulation of the trans-oesophageal echo probe to devi-
ate the oesophagus.15 Dedicated devices have also been studied such
as the Balloon Retractor.16 These methods are imperfect and poten-
tially harmful. A recent large multi-centre study showed that trans-
oesophageal echo probe insertion and manipulation is an important
cause of mortality in general anaesthetic cases undergoing cardiotho-
racic surgery or cardiac procedures with an incidence of 1 in 3000
and a mortality rate of 40% to those that sustained oesophageal in-
jury.17 Mechanical deviation of the oesophagus by any device could
cause similar complications.
Oesophageal temperature measurement is commonly used. For
our control group, we adopted the standard approach in our centre:
Use of a single-point temperature probe for all cases. There is no
proof that this method improves safety compared with ablations per-
formed without oesophageal temperature measurement, and it
comes at a cost to efficiency as time is expended in adjusting the posi-
tion of the probe and waiting for the temperature to return to base-
line each time a temperature rise occurs. These factors may have
reduced efficiency and perhaps even efficacy in our control group.
The effect of oesophageal thermal protection on efficiency and safety
might have been different if the control population had not had any
temperature probe or if a multi-point probe had been used.
There are considerable differences between the oesophageal tem-
perature probes used in AF ablation. Turagam et al.18 investigated the
characteristics of a range of them. Solid shaft and acoustascopes and
single-sensor probes and multi-sensor probes were compared in a
series of experiments, measuring the thermal response of each probe
after immersion in temperature-set water baths. The probes were
equilibrated in water bath 1 at 37C and then quickly transferred to
water bath 2 at 45C. The time taken to register the full extent of the
temperature change varied from 6.2 to 19.7s, with the quickest re-
sponse given by multi-sensor probes, followed by single-sensor
probes and with acoustascopes responding least rapidly.
Although the Turagam study did not replicate the exact conditions
found in the clinical situation, it confirmed the notion that different
probes can give substantially different results, and some could give a
false sense of security during ablation. The probes also differ in price
and ease of insertion to the correct level. The apparent superiority of
multi-sensor probes in detecting temperature rises in this study may
also have a paradoxical effect. Increased oesophageal thermal injury
was observed after use of multi-sensor probes in one study com-
pared with single-sensor probes,19 probably due to bipolar thermal
energy transmission during RF ablation. The probe used in the con-
trol group of our study was chosen as an example of the sort that in
our experience is most commonly used.
Operator restraint in the power delivered to the left atrial poste-
rior wall was the first strategy shown to reduce the risk of fistula.
More recently, limitation in the use of contact force has been shown
to help.20 Unfortunately, this conservative methodology risks pro-
ducing less effective lesion sets, hindering procedural success, and
fostering inefficient workflow.
Previous studies on oesophageal cooling
Previous small studies have investigated the efficacy of oesophageal
cooling during ablation. Although individually inconclusive, taken to-
gether, these show clear evidence of protection, but the effect is
small.21,22 The small magnitude of the protection is unsurprising,
given the limited heat extraction capability of the methods used.
Oesophageal cooling using the ensoETM device is simple and easily
standardized; it is also a much more effective heat extractor than the
methods investigated by previous studies.
Gastric motility
Previous post-ablation endoscopic studies were either focused on
mucosal lesions or functional pathology.4,23 Our trial protocol in-
cluded a detailed assessment of gastric motility as well as the oeso-
phageal mucosa. The IMPACT study shows a non-significant excess
of both endoscopically defined delay in gastric emptying and in
Oesophageal protection during AF ablation 9
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symptoms related to this condition in the control group compared
with patients receiving thermal protection.
Applicability of the method
The use of the ensoETM device in our unit encountered no significant
obstacle. The work-flow was smooth and no complication occurred.
We had the benefit of the availability of general anaesthesia for all the
cases studied and the benefit of a spacious operating room. The con-
sole occupies much less space than either the anaesthetic machine or
any of the mapping systems that we use, but in a cramped and over-
filled lab it might be an unwelcome addition. We do not have direct
experience of the use of the device in patients undergoing proce-
dures under conscious sedation; it is feasible to do this, but the safety
and acceptability have not been quantified.
The ensoETM device costs less than multi-sensor temperature
monitoring devices that are routinely used, though more than the sin-
gle-point probe used in our control cases. Based on an incidence of
atrio-oesophageal fistula of 0.1%, representing the lower end of the
range generally reported,1 and assuming that the 83% reduction in
mild to moderate thermal lesions seen with the ensoETM in our
study is mirrored in the prevention of fistula, we would need to pro-
tect 1160 patients to prevent one fistula. The relevance of this cost-
benefit calculation will vary between centres.
Limitations
We have not proved that the use of the ensoETM device eliminates
the possibility of atrio-oesophageal fistula formation. A far larger trial
would be required to answer this critical question.
Operators participating in the study were not and could not have
been blinded to the randomization. We were conscious of the risk
that a perceived protection might foster recklessness by the opera-
tors, so all were exhorted to adhere as closely as possible to their
standard methods and lesion sets. The data collected on ablation
power and contact force suggests that they did so. This strict adher-
ence to standard methodology may have contributed to the high
level of oesophageal protection observed. It should not be inter-
preted as a licence to abandon all restraint in ablating near the
oesophagus.
The control group followed standard practice at our centre: oeso-
phageal protection was offered in the form of a single sensor probe.
This is limited in its ability to sense temperature change at the site of
greatest risk to the oesophagus with sufficient rapidity to prevent in-
jury. The results found in our control group may not be generalizable
to temperature measurement using other measurement devices.
Redo procedures and first-time ablations were included, poten-
tially reducing the power of the study to demonstrate significant dif-
ferences. The follow-up duration available on these patients is still
not sufficient to exclude the possibility of an effect of oesophageal
cooling on the formation of thermal lesions in the adjacent atrium.
Longer follow-up on this cohort will be needed.
Conclusions
Thermal protection of the oesophagus significantly reduces ablation-
related thermal injury compared with standard care. This method of
oesophageal protection is safe and does not compromise the efficacy
or efficiency of the ablation procedure.
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